StockData
Actinium Pharmaceuticals, Inc. logo

Actinium Pharmaceuticals, Inc. (ATNM) stock

ATNMNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 10/3081% below fair value
$1.08−0.27 (-20.00%)

Close on Nov 18, 2026Market cap $33.96MP/E 3.0Yield –

Actinium Pharmaceuticals revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Actinium Pharmaceuticals's revenue for the twelve months ending Dec 31, 2025 was $90.00K. For fiscal 2025 it was $90.00K, up 11.1% from the year before. The highest annual figure on record is $1.14M in fiscal 2021.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$90.00K+11.1%
FY2023Dec 31, 2023$81.00K-92.1%
FY2022Dec 31, 2022$1.03M-10.0%
FY2021Dec 31, 2021$1.14M–
FY2011Dec 31, 2011$0–
FY2010Dec 31, 2010$0–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$35.00M+77677.8%
Q4 FY2025Dec 31, 2025$0-100.0%
Q3 FY2025Sep 30, 2025$90.00K-90.4%
Q4 FY2022Dec 31, 2022$0-100.0%
Q3 FY2022Sep 30, 2022$45.00K-80.7%
Q2 FY2022Jun 30, 2022$45.00K-83.1%
Q1 FY2022Mar 31, 2022$940.00K+51.1%
Q4 FY2021Dec 31, 2021$23.00K–
Q3 FY2021Sep 30, 2021$233.00K–
Q2 FY2021Jun 30, 2021$266.00K–
Q1 FY2021Mar 31, 2021$622.00K–

More Actinium Pharmaceuticals figures

See a number that looks wrong?